Literature DB >> 7786995

Guidelines for monitoring efficacy and toxicity responses in clinical trials.

R J Cook1, V T Farewell.   

Abstract

There is currently a need for clinical trial methodology that allows formal consideration of toxicity responses. Since a complete evaluation of an experimental therapy addresses both relative efficacy and relative toxicity, general methods for handling bivariate response data are of interest. A procedure for sequentially analysing both efficacy and toxicity data is presented. The procedure is designed to allow early termination due to efficacy results, toxicity results, or both. The method is based on modified marginal sequential analyses, accounting for bivariate correlated responses and multiple analyses over time. The theory is presented in the context of normally distributed responses. Extensions to bivariate failure time data are indicated and an example from a kidney transplant study demonstrates the procedure.

Entities:  

Mesh:

Year:  1994        PMID: 7786995

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  10 in total

Review 1.  Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review.

Authors:  Toshimitsu Hamasaki; Scott R Evans; Koko Asakura
Journal:  J Biopharm Stat       Date:  2017-10-30       Impact factor: 1.051

2.  A Rejection Principle for Sequential Tests of Multiple Hypotheses Controlling Familywise Error Rates.

Authors:  Jay Bartroff; Jinlin Song
Journal:  Scand Stat Theory Appl       Date:  2015-05-25       Impact factor: 1.396

3.  Group-sequential logrank methods for trial designs using bivariate non-competing event-time outcomes.

Authors:  Tomoyuki Sugimoto; Toshimitsu Hamasaki; Scott R Evans; Susan Halabi
Journal:  Lifetime Data Anal       Date:  2019-04-12       Impact factor: 1.588

4.  Assessing the impact of safety monitoring on the efficacy analysis in large Phase III group sequential trials with non-trivial safety event rate.

Authors:  Yanqiu Weng; Yuko Y Palesch; Stacia M DeSantis; Wenle Zhao
Journal:  J Biopharm Stat       Date:  2015-05-26       Impact factor: 1.051

5.  Interim evaluation of efficacy or futility in group-sequential trials with multiple co-primary endpoints.

Authors:  Koko Asakura; Toshimitsu Hamasaki; Scott R Evans
Journal:  Biom J       Date:  2016-10-19       Impact factor: 2.207

6.  Sequential Tests of Multiple Hypotheses Controlling Type I and II Familywise Error Rates.

Authors:  Jay Bartroff; Jinlin Song
Journal:  J Stat Plan Inference       Date:  2014-10-01       Impact factor: 1.111

7.  Adjustment on the Type I Error Rate for a Clinical Trial Monitoring for both Intermediate and Primary Endpoints.

Authors:  Susan Halabi
Journal:  J Biom Biostat       Date:  2012-05-19

8.  Monitoring futility in a two-by-two factorial design: the SPS3 experience.

Authors:  Leslie A McClure; Christopher S Coffey; George Howard
Journal:  Clin Trials       Date:  2013-02-01       Impact factor: 2.486

9.  Impact of safety monitoring on error probabilities of binary efficacy outcome analyses in large phase III group sequential trials.

Authors:  Yanqiu Weng; Wenle Zhao; Yuko Palesch
Journal:  Pharm Stat       Date:  2012-05-16       Impact factor: 1.894

10.  Choice of futility boundaries for group sequential designs with two endpoints.

Authors:  Svenja Schüler; Meinhard Kieser; Geraldine Rauch
Journal:  BMC Med Res Methodol       Date:  2017-08-08       Impact factor: 4.615

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.